# Dose-ranging Study of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications of Early Decompensated Liver Cirrhosis

> **NCT01904409** · PHASE2 · COMPLETED · sponsor: **Bausch Health Americas, Inc.** · enrollment: 420 (actual)

## Conditions studied

- Liver Cirrhosis

## Interventions

- **DRUG:** Placebo
- **DRUG:** Rifaximin SSD 40 mg IR tablet
- **DRUG:** Rifaximin SSD 80 mg IR tablet
- **DRUG:** Rifaximin SSD 40 mg SER tablet
- **DRUG:** Rifaximin SSD 80 mg SER tablet
- **DRUG:** Rifaximin SSD 80mgIR/80mgSER tablet

## Key facts

- **NCT ID:** NCT01904409
- **Lead sponsor:** Bausch Health Americas, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06
- **Primary completion:** 2015-06
- **Final completion:** 2015-07
- **Target enrollment:** 420 (ACTUAL)
- **Last updated:** 2019-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01904409

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01904409, "Dose-ranging Study of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications of Early Decompensated Liver Cirrhosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01904409. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*